Loading
A phase 1/2 trial of Temozolomide in melanoma and prostate cancer, run by Sapience Therapeutics, active and no longer recruiting.
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04478279 by Sapience Therapeutics, with 125 participants enrolled, started 2020-07-01 and due to reach its primary completion in 2026-12. Interventions recorded: ST101, Temozolomide, Radiation. Conditions listed: Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.